Publications
Recent Publications
2024
Abusamra SM, Solorzano MA, Quarles J, Luke M, Patel M, Vince R Jr, Jiang R, Volin J, Jacobs MF, Kaffenberger S, Salami SS, Palmbos P, Caram MEV, Hollenbeck BK, Palapattu GS, Merajver SD, Stoffel EM, Hafron J, Morgan TM, Reichert ZR. Detection of Germline Variants in Patients with Localized and Metastatic Prostate Cancer Through Guideline-Based Testing. Urol Pract. 2024 Oct 9:101097UPJ0000000000000727. doi: 10.1097/UPJ.0000000000000727. Epub ahead of print. PMID: 39383006.
Tondo-Steele K, Milliron KJ, Siedel JH, Uppal S, Merajver SD, McLean K. Germline genetic testing reveals pathogenic variants in uterine serous carcinoma patients. Gynecol Oncol Rep. 2024 Sep 2; 55:101498. doi: 10.1016/j.gore.2024.101498. PMID: 39297075; PMCID: PMC11408757.
Niu Z, Kozminsky M, Day KC, Broses LJ, Henderson ML, Patsalis C, Tagett R, Qin Z, Blumberg S, Reichert ZR, Merajver SD, Udager AM, Palmbos PL, Nagrath S, Day ML. Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics. Neoplasia. 2024 Aug 21; 57:101036. doi: 10.1016/j.neo.2024.101036. Epub ahead of print. PMID: 39173508.
Merrill NM, Kaffenberger SD, Bao L, Vandecan N, Goo L, Apfel A, Cheng X, Qin Z, Liu CJ, Bankhead A, Wang Y, Kathawate V, Tudrick L, Serhan HA, Farah Z, Ellimoottil C, Hafez KS, Herrel LA, Montgomery JS, Morgan TM, Salami SS, Weizer AZ, Ulintz PJ, Day ML, Soellner MB, Palmbos PL, Merajver SD, Udager AM. Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response. Eur Urol. 2024 Aug 17: S0302-2838(24)02408-4. doi: 10.1016/j.eururo.2024.05.026. Epub ahead of print. PMID: 39155193.
Serhan HA, Bao L, Cheng X, Qin Z, Liu CJ, Heth JA, Udager AM, Soellner MB, Merajver SD, Morikawa A, Merrill NM. Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion. NPJ Breast Cancer. 2024 Jun 10;10(1):43. doi: 10.1038/s41523-024-00656-0. PMID: 38858374; PMCID: PMC11164988.
Laws A, Leonard S, Hershey E, Stokes S, Vincuilla J, Sharma E, Milliron K, Garber JE, Merajver SD, King TA, Pilewskie ML. Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions. Ann Surg Oncol. 2024 May;31(5):3120-3127. doi: 10.1245/s10434-024-14947-0. Epub 2024 Jan 23. PMID: 38261128.
Mao W, Vandecan NM, Bingham CR, Tsang PK, Ulintz P, Sexton R, Bochar DA, Merajver SD, Soellner MB. Selective and Potent PROTAC Degraders of c-Src Kinase. ACS Chem Biol. 2024 Jan 19;19(1):110-116. doi: 10.1021/acschembio.3c00548. Epub 2023 Dec 19. PMID: 38113191.
Liu Y, Joy ST, Henley MJ, Croskey A, Yates JA, Merajver SD, Mapp AK. Inhibition of CREB Binding and Function with a Dual-Targeting Ligand. Biochemistry. 2024 Jan 2;63(1):1-8. doi: 10.1021/acs.biochem.3c00469. Epub 2023 Dec 12. PMID: 38086054; PMCID: PMC10836052.
2023
Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, Arun B, Buys SS, Cheng H, Domchek SM, Friedman S, Giri V, Goggins M, Hagemann A, Hendrix A,
Hutton ML, Karlan BY, Kassem N, Khan S, Khoury K, Kurian AW, Laronga C, Mak JS, Mansour J, McDonnell K, Menendez CS, Merajver SD, Norquist BS, Offit K,
Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Visvanathan K, Welborn J, Wick MJ, Wood M, Yurgelun MB, Dwyer MA, Darlow SD. NCCN Guidelines®
Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw. 2023 Oct;21(10):1000-1010. doi:
10.6004/jnccn.2023.0051. PMID: 37856201.
Pleasant VA, Purkiss AS, Merjaver SD. Redefining the "crown": Approaching chemotherapy-induced alopecia among Black patients with breast cancer. Cancer. 2023 Jun 1;129(11):1629-1633. doi: 10.1002/cncr.34732. Epub 2023 Mar 30. PMID: 37158640.
Morikawa A, Li J, Ulintz P, Cheng X, Apfel A, Robinson D, Hopkins A, Kumar-Sinha C, Wu YM, Serhan H, Verbal K, Thomas D, Hayes DF, Chinnaiyan AM, Baladandayuthapani V, Heth J, Soellner MB, Merajver SD, Merrill N. Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment. Cancer Res Commun. 2023 Jun 21;3(6):1093-1103. doi: 10.1158/2767-9764.CRC-22-0492. PMID: 37377606; PMCID: PMC10284082.
Westerhof TM, Yang BA, Merill NM, Yates JA, Altemus M, Russell L, Miller AJ, Bao L, Wu Z, Ulintz PJ, Aguilar CA, Morikawa A, Castro MG, Merajver SD, Oliver CR. Blood-brain barrier remodeling in an organ-on-a-chip device shows Dkk1 to be a regulator of early metastasis. Adv Nanobiomed Res. 2023 Apr;3(4):2200036. doi: 10.1002/anbr.202200036. Epub 2023 Feb 5. PMID: 37234365; PMCID: PMC10208594.
Pattelli ON, Valdivia EM, Beyersdorf MS, Regan CS, Rivas M, Merajver SD, Cierpicki T, Mapp AK. A lipopeptidomimetic of transcriptional activation domains selectively disrupts Med25 PPIs. bioRxiv [Preprint]. 2023 Mar 25:2023.03.24.534168. doi: 10.1101/2023.03.24.534168. PMID: 36993479; PMCID: PMC10055422.
Fleege NMG, Pierce-Gjeldum D, Swartz LK, Verbal K, Merajver S, Friese CR, Kiyota A, Heth J, Leung D, Smith SR, Gabel N, Kim MM, Morikawa A. IMPACT the Brain: A Team-Based Approach to Management of Metastatic Breast Cancer with CNS Metastases. JCO Oncol Pract. 2023 Jan;19(1): e67-e77. doi: 10.1200/OP.22.00291. Epub 2022 Oct 12. PMID: 36223556; PMCID: PMC9870235.
2022
Achreja A, Yu T, Mittal A, Choppara S, Animasahun O, Nenwani M, Wuchu F, Meurs N, Mohan A, Jeon JH, Sarangi I, Jayaraman A, Owen S, Kulkarni R, Cusato M, Weinberg F, Kweon HK, Subramanian C, Wicha MS, Merajver SD, Nagrath S, Cho KR, DiFeo A, Lu X, Nagrath D. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer. Nat Metab. 2022 Sep;4(9):1119-1137. doi: 10.1038/s42255-022-00636-3. Epub 2022 Sep 21. PMID: 36131208.
Abusamra SM, Solorzano MA, Luke M, Quarles J, Jacobs MF, Das S, Kasputis A, Okoth LA, Patel M, Seymore M, Caram MEV, Dunn RL, Merajver SD, Stoffel EM, Reichert ZR, Morgan TM. Satisfaction With Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer. J Urol. 2022 Nov;208(5):1007-1017. doi: 10.1097/JU.0000000000002865. Epub 2022 Aug 5. PMID: 35930793.
McCain LA, Milliron KJ, Cook AM, Paquette R, Parvaz JB, Ernst SD, Kittendorf AL, Harper DM, Zazove P, Arthurs J, Tippie JA, Hulswit B, Schroeder LF, Keren DF, Merajver SD. Implementation of INHERET, an Online Family History and Cancer Risk Interpretation Program for Primary Care and Specialty Clinics. J Natl Compr Canc Netw. 2022 Jan;20(1):63-70. doi: 10.6004/jnccn.2021.7072. PMID: 34991067.
2021
Phadke S, Lopez-Barcons L, Vandecan N, Wu Z, Johnson TK, Lachacz EJ, Merajver SD, Soellner MB. Insights into the modular design of kinase inhibitors and application to Abl and Axl. RSC Med Chem. 2021 Nov 5;13(1):64-71. doi: 10.1039/d1md00296a. PMID: 35224497; PMCID: PMC8792823.
Pedrazzani C, Ming C, Bürki N, Caiata-Zufferey M, Chappuis PO, Duquette D, Heinimann K, Heinzelmann-Schwarz V, Graffeo-Galbiati R, Merajver SD, Milliron KJ, Monnerat C, Pagani O, Rabaglio M, Katapodi MC on behalf of the CASCADE Consortium. Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More than 10 Years. Cancers. 2021; 13(24):6254. https://doi.org/10.3390/cancers13246254.
Sessine MS, Das S, Park B, Salami SS, Kaffenberger SD, Kasputis A, Solorzano M, Luke M, Vince RA, Kaye DR, Borza T, Stoffel EM, Cobain E, Merajver SD, Jacobs MF, Milliron KJ, Caba L, van Neste L, Mondul AM, Morgan TM. Initial Findings from a High Genetic Risk Prostate Cancer Clinic. Urology. 2021 Oct; 156:96-103. doi: 10.1016/j.urology.2021.05.078. Epub 2021 Jul 17. PMID: 34280438.
Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage MS, Haase S, Ventosa M, Taher A, Kamran N, Zhang L, Faisal SM, Núñez FJ, Garcia-Fabiani MB, Al-Holou WN, Orringer D, Hervey-Jumper S, Heth J, Patil PG, Eddy K, Merajver SD, Ulintz PJ, Welch J, Gao C, Liu J, Núñez G, Hambardzumyan D, Lowenstein PR, Castro MG. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021 Oct;7(40): eabh3243. doi: 10.1126/sciadv. abh3243. Epub 2021 Sep 29. PMID: 34586841; PMCID: PMC8480930.
Abraham HG, Ulintz PJ, Goo L, Yates JA, Little AC, Bao L, Wu Z, Merajver SD. RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers. Front Oncol. 2021 Aug 26; 11:712041. doi: 10.3389/fonc.2021.712041. PMID: 34513691; PMCID: PMC8428533.
Larouche JA, Mohiuddin M, Choi JJ, Ulintz PJ, Fraczek P, Sabin K, Pitchiaya S, Kurpiers SJ, Castor-Macias J, Liu W, Hastings RL, Brown LA, Markworth JF, De Silva K, Levi B, Merajver SD, Valdez G, Chakkalakal JV, Jang YC, Brooks SV, Aguilar CA. Murine muscle stem cell response to perturbations of the neuromuscular junction are attenuated with aging. Elife. 2021 Jul 29;10: e66749. doi: 10.7554/eLife.66749. PMID: 34323217; PMCID: PMC8360658.
Garlick JM, Sturlis SM, Bruno PA, Yates JA, Peiffer AL, Liu Y, Goo L, Bao L, De Salle SN, Tamayo-Castillo G, Brooks CL 3rd, Merajver SD, Mapp AK. Norstictic Acid Is a Selective Allosteric Transcriptional Regulator. J Am Chem Soc. 2021 Jun 30;143(25):9297-9302. doi: 10.1021/jacs.1c03258. Epub 2021 Jun 17. PMID: 34137598.
McInnis MG, Thompson SB, Merajver SD, Schneider CE. Suicide prevention and mood disorders: Self-exclusion agreements for firearms as a suicide prevention strategy. Asia Pac Psychiatry. 2021 Sep;13(3): e12455. doi: 10.1111/appy.12455. Epub 2021 Mar 8. PMID: 33686800; PMCID: PMC8459244.
Jiagge EM, Ulintz PJ, Wong S, McDermott SP, Fossi SI, Suhan TK, Hoenerhoff MJ, Bensenhaver JM, Salem B, Dziubinski M, Oppong JK, Aitpillah F, Ishmael K, Osei-Bonsu E, Adjei E, Baffour A, Aldrich J, Kurdoglu A, Fernando K, Craig DW, Trent JM, Li J, Chitale D, Newman LA, Carpten JD, Wicha MS, Merajver SD. Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry. Breast Cancer Res Treat. 2021 Apr;186(2):391-401. doi: 10.1007/s10549-021-06097-8. Epub 2021 Feb 12. PMID: 33576900.
Lloyd JP, Soellner MB, Merajver SD, Li JZ. Impact of between-tissue differences on pan-cancer predictions of drug sensitivity. PLoS Comput Biol. 2021 Feb 25;17(2):e1008720. doi: 10.1371/journal.pcbi.1008720. PMID: 33630864; PMCID: PMC7906305.
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC; Karlan BY, Khan S, Klein C, Kohlmann W; CGC; Kurian AW, Laronga C, Litton JK, Mak JS; LCGC; Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC; Senter-Jamieson L; CGC; Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001. PMID: 33406487.